371 related articles for article (PubMed ID: 2790807)
1. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.
Mayer LD; Tai LC; Ko DS; Masin D; Ginsberg RS; Cullis PR; Bally MB
Cancer Res; 1989 Nov; 49(21):5922-30. PubMed ID: 2790807
[TBL] [Abstract][Full Text] [Related]
2. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors.
Mayer LD; Bally MB; Loughrey H; Masin D; Cullis PR
Cancer Res; 1990 Feb; 50(3):575-9. PubMed ID: 2297698
[TBL] [Abstract][Full Text] [Related]
3. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes.
Harasym TO; Cullis PR; Bally MB
Cancer Chemother Pharmacol; 1997; 40(4):309-17. PubMed ID: 9225948
[TBL] [Abstract][Full Text] [Related]
4. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients.
Mayer LD; Tai LC; Bally MB; Mitilenes GN; Ginsberg RS; Cullis PR
Biochim Biophys Acta; 1990 Jun; 1025(2):143-51. PubMed ID: 2364073
[TBL] [Abstract][Full Text] [Related]
5. Lipophilic cisplatin analogues entrapped in liposomes: role of intraliposomal drug activation in biological activity.
Perez-Soler R; Khokhar AR
Cancer Res; 1992 Nov; 52(22):6341-7. PubMed ID: 1423280
[TBL] [Abstract][Full Text] [Related]
6. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors.
Mayer LD; Dougherty G; Harasym TO; Bally MB
J Pharmacol Exp Ther; 1997 Mar; 280(3):1406-14. PubMed ID: 9067330
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
Parr MJ; Masin D; Cullis PR; Bally MB
J Pharmacol Exp Ther; 1997 Mar; 280(3):1319-27. PubMed ID: 9067319
[TBL] [Abstract][Full Text] [Related]
8. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
9. Liposomal doxorubicin.
Tardi PG; Boman NL; Cullis PR
J Drug Target; 1996; 4(3):129-40. PubMed ID: 8959485
[TBL] [Abstract][Full Text] [Related]
10. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
Allen TM; Mumbengegwi DR; Charrois GJ
Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
[TBL] [Abstract][Full Text] [Related]
12. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia.
Mayer LD; Nayar R; Thies RL; Boman NL; Cullis PR; Bally MB
Cancer Chemother Pharmacol; 1993; 33(1):17-24. PubMed ID: 8269584
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation.
Bhatia A; Kumar R; Katare OP
J Pharm Pharm Sci; 2004 Jul; 7(2):252-9. PubMed ID: 15367383
[TBL] [Abstract][Full Text] [Related]
14. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
15. Reduced toxicity and enhanced antitumor effects in mice of the ionophoric drug valinomycin when incorporated in liposomes.
Daoud SS; Juliano RL
Cancer Res; 1986 Nov; 46(11):5518-23. PubMed ID: 3756900
[TBL] [Abstract][Full Text] [Related]
16. Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation.
Mayer LD; Reamer J; Bally MB
J Pharm Sci; 1999 Jan; 88(1):96-102. PubMed ID: 9874708
[TBL] [Abstract][Full Text] [Related]
17. Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model.
Storm G; Roerdink FH; Steerenberg PA; de Jong WH; Crommelin DJ
Cancer Res; 1987 Jul; 47(13):3366-72. PubMed ID: 3581073
[TBL] [Abstract][Full Text] [Related]
18. A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines.
Papagiannaros A; Hatziantoniou S; Dimas K; Papaioannou GT; Demetzos C
Biomed Pharmacother; 2006 Jan; 60(1):36-42. PubMed ID: 16271845
[TBL] [Abstract][Full Text] [Related]
19. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
[TBL] [Abstract][Full Text] [Related]
20. Effect of cholesterol in various liposomal compositions on the in vivo toxicity, therapeutic efficacy, and tissue distribution of amphotericin B.
Ahmad I; Sarkar AK; Bachhawat BK
Biotechnol Appl Biochem; 1990 Oct; 12(5):550-6. PubMed ID: 2288711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
